This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Akili Crescita futura

Future criteri di controllo 2/6

Akili is forecast to grow revenue at 44.2% per annum.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Healthcare Services crescita degli utili	0%
Tasso di crescita dei ricavi	44.2%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	21 Jun 2024

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Previsioni di crescita degli utili e dei ricavi

BMV:AKLI * - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	9	N/A	N/A	N/A	1
12/31/2025	6	N/A	N/A	N/A	1
12/31/2024	4	N/A	N/A	N/A	1
3/31/2024	2	-49	-49	-49	N/A
12/31/2023	2	-59	-58	-58	N/A
9/30/2023	1	-65	-70	-70	N/A
6/30/2023	0	2	-73	-73	N/A
3/31/2023	0	-14	-80	-80	N/A
12/31/2022	0	-19	-84	-84	N/A
9/30/2022	0	-26	-81	-81	N/A
6/30/2022	0	-99	-75	-74	N/A
3/31/2022	0	-144	-68	-67	N/A
12/31/2021	1	-127	-54	-54	N/A
9/30/2021	0	-111	-43	-42	N/A
12/31/2020	4	-26	-25	-25	N/A
12/31/2019	20	-21	-30	-29	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Insufficient data to determine if AKLI *'s forecast earnings growth is above the savings rate (7.8%).

Guadagni vs Mercato: Insufficient data to determine if AKLI *'s earnings are forecast to grow faster than the MX market

Guadagni ad alta crescita: Insufficient data to determine if AKLI *'s earnings are expected to grow significantly over the next 3 years.

Ricavi vs Mercato: AKLI *'s revenue (44.2% per year) is forecast to grow faster than the MX market (6.9% per year).

Ricavi ad alta crescita: AKLI *'s revenue (44.2% per year) is forecast to grow faster than 20% per year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Insufficient data to determine if AKLI *'s Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Akili Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Akili, Inc.(NasdaqCM:AKLI) dropped from NASDAQ Composite Index

Akili to Delist from Nasdaq

Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with AdHD Through a Video Game

Virtual Therapeutics Corp. entered into an agreement to acquire Akili, Inc. (NasdaqCM:AKLI) for $35 million.

Virtual Therapeutics Corp. entered into an agreement to acquire Akili, Inc. (NasdaqCM:AKLI) for $35 million.

Akili, Inc. to Reduce Workforce

Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product

Akili, Inc. Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC

Full year 2023 earnings released: US$0.76 loss per share (vs US$0.64 loss in FY 2022)

High number of new and inexperienced directors

Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx®? for Pediatric Adhd Patients in Japan

Akili, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Akili, Inc. Announces Resignation of Santosh Shanbhag as Chief Financial Officer, Effective on January 12, 2024

Akili Receives Non-Compliance Notice from Nasdaq

Akili, Inc. Announces Kenneth Ehlert Resigns as A Member of the Board of Director, Member of the Audit Committee and Nominating and Corporate Governance Committee of the Board

Akili, Inc. Receives Authorization from the U.S. Food and Drug Administration

Akili Receives Non-Compliance Notice from Nasdaq

Akili, Inc. Releases Results from A New Study Examining the Way in Which Adhd Impacting the U.S. Workforce

Akili, Inc. Announces CEO Changes

Akili Releases EndeavorOTC on Android Devices, Expanding Treatment Access for Millions of Adults with Adhd

High number of new and inexperienced directors

Akili Releases EndeavorOTC Video Game Treatment to Improve Attention in Adults with Adad

Akili, Inc. to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with Adolescents At 2023

First quarter 2023 earnings released: US$0.27 loss per share (vs US$17.96 loss in 1Q 2022)

High number of new and inexperienced directors

High number of new and inexperienced directors

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita